Abstract Number: LB15 • ACR Convergence 2025
Dietary Fiber Supplementation Enhances Methotrexate Response and Restores Th17/Treg Balance in Rheumatoid Arthritis: Results from the Superfibre Randomized Trial
Background/Purpose: Gut dysbiosis and Th17/Treg imbalance contribute to rheumatoid arthritis (RA). Additionally, methotrexate (MTX) efficacy depends on gut microbiota composition, especially on the presence of B.…Abstract Number: 2639 • ACR Convergence 2025
Gut Microbiome Signatures Forecast Clinical Response to Methotrexate in Treatment-Naïve Early Rheumatoid Arthritis
Background/Purpose: Oral methotrexate (MTX) is the cornerstone treatment for newly diagnosed rheumatoid arthritis (RA), yet up to 50% of patients do not respond adequately. Early…Abstract Number: 1329 • ACR Convergence 2025
Relationship Between Circulating Bacterial Small RNAs, Methotrexate Response, and Microbiome in New Onset Rheumatoid Arthritis
Background/Purpose: Microbiome and microbial products are possible contributors and predictors to methotrexate (MTX) response variability. Bacterial small RNAs (sRNAs) are found in human plasma and…Abstract Number: 0322 • ACR Convergence 2025
Metabolites Reflective of the Gut Microbiome Relate to Future Incident Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Background/Purpose: Numerous cross-sectional and animal studies have linked an altered gut microbiome to osteoarthritis (OA). Human studies are needed to explore the association between the…Abstract Number: 2622 • ACR Convergence 2025
Oral Microbiome Dysbiosis and Oral-gut Microbial Network Disruption in Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study
Background/Purpose: The oral microbiome plays a critical role in modulating systemic inflammation and maintaining immune homeostasis, partly through its interactions with the gut microbiome. Although…Abstract Number: 1119 • ACR Convergence 2025
Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their use is often limited by immune-related adverse events (irAEs), particularly in barrier tissues such…Abstract Number: 0101 • ACR Convergence 2025
Enrichment of putative bacteria-reactive gut-derived IL-17+ tissue resident memory helper T cells in arthritic ankles in the SKG mouse model of spondyloarthritis
Background/Purpose: In spondyloarthropathy (SpA), arthritis is often associated with gut inflammation. The strong genetic association with HLA-B27 implicates involvement of T cells, but how gut…Abstract Number: 2590 • ACR Convergence 2025
Translating findings on urate-metabolizing bacterial genes and urate levels at the human population level: a gut microbiome analysis of three independent cohorts of men and women
Background/Purpose: Approximately 21% of US adults have hyperuricemia, the causal precursor for gout. Human cells do not degrade urate (due to uricase gene inactivation). However,…Abstract Number: 1032 • ACR Convergence 2025
Exploring the role of the gut microbiome in gout: Prospective analysis of dietary fiber intake and the risk of gout
Background/Purpose: The role of the gut microbiome has been increasingly implicated in the pathogenesis of gout. For instance, gout patients have shown depletions of bacteria…Abstract Number: 0088 • ACR Convergence 2025
Imbalance of Inflammation-Regulating Microorganisms and Predicted Metabolomic Pathways Associates With Disease Evolution in Individuals At-Risk for Rheumatoid Arthritis
Background/Purpose: The mucosal origins hypothesis of RA proposes that immune responses to microorganisms at mucosal sites (e.g. intestine) lead to systemic inflammation and autoimmunity. Little…Abstract Number: 2589 • ACR Convergence 2025
Multi-omics Integration Reveals Gut Microbiota–Metabolite Dysregulation in Gout with Metabolic Syndrome
Background/Purpose: Gout is a metabolic disorder driven by abnormalities in urate metabolism and chronic inflammation. Recent studies suggest that gout is not limited to joint…Abstract Number: 0938 • ACR Convergence 2025
Short Term Antibiotic Treatment Improves the Neurobehavioral Phenotype of MRL/lpr Mice
Background/Purpose: Neuropsychiatric lupus (NPSLE) is a common and prognostically significant manifestation of SLE, affecting 20-40% of lupus patients. The ACR identified 19 clinical syndromes associated…Abstract Number: 0054 • ACR Convergence 2025
Microbial Cues Promote Arthritis and Alter T Cell Selection in SKG Mice
Background/Purpose: Dysbiosis of the gut microbiota has been linked to rheumatoid arthritis (RA), but it remains unclear whether these microbial alterations are causal or secondary…Abstract Number: 2399 • ACR Convergence 2025
Identification of an LN endotype linked to intestinal expansion of Pathogenic Strains of a Pathobiont Bacterium that induces Systemic Thrombo-inflammatory Pathways directly measurable in Urine
Background/Purpose: During disease, ~50% of SLE patients develop lupus nephritis (LN), one of the most serious complication. Despite the best therapy, within 15 years, ~20%…Abstract Number: 0935 • ACR Convergence 2025
Oral Antibiotic Treatment Reduces Anxiety in a Murine Model of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Background/Purpose: Unclear mechanisms underlying diffuse NPSLE (anxiety, cognitive dysfunction) lead to the devastating impact of this disease on patients’ health-related quality-of-life. Dysbiosis of gut microbiota…
- 1
- 2
- 3
- …
- 13
- Next Page »
